OOIR: Observatory of International Research

Papers

(The H4-Index of JPAD-Journal of Prevention of Alzheimers Disease is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
Herpes zoster and dementia : more evidences for a causal link	611
Gene and genetic therapies in Alzheimer’s disease and other dementias	131
Validation of the CogDrisk Instrument as Predictive of Dementia in Four General Community-Dwelling Populations	131
Informing etiological heterogeneity of mild cognitive impairment and risk for progression to dementia with plasma p-tau217	116
The Geras Solutions Cognitive Test for Assessing Cognitive Impairment: Normative Data from a Population-Based Cohort	90
Erratum to: Cerebral Phospho-Tau Acts Synergistically with Soluble Aβ42 Leading to Mild Cognitive Impairment in AAV-AD Rats	88
Ten Years after the National Alzheimer's Plan: Dementia Remains a Hidden Syndrome in France	83
Lecanemab over a two-year duration: Key insights from a regional specialty medical center	78
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease	67
Effects of Non-Invasive Brain Stimulation on Alzheimer's Disease	65
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data	62
On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use	56
Prevention of dementia using mobile phone applications (PRODEMOS) – a health-economic cost-utility analysis in people aged 55–75 years with low socio-economic status	54
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation	46
Estimation of the value-based price of a blood test for Alzheimer’s disease pathology in primary and specialty care in the U.S.	46
Long-term fasting insulin variability and cognitive function: Insights from the CARDIA study	42
Neuroprotective Effects of IVIG against Alzheimer's Disease via Regulation of Antigen Processing and Presentation by MHC Class I Molecules in 3xTg-AD Mice	42
‘Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings	40
Utility of plasma GFAP as a secondary endpoint for clinical trials in Alzheimer’s disease	40
AMBAR: A Therapeutical Approach for Alzheimer's Disease Patients Regardless of Amyloid Status	39
Elecsys Cerebrospinal Fluid Assays Accurately Distinguish Alzheimer's Disease from Frontotemporal Lobar Degeneration	38
Introduction to the Special Issue on the A4 Study	38
A systematic review of targeted dementia risk reduction interventions in middle-aged adults in Primary Care	37
LMTK2 and CRB1 are two novel risk genes for Alzheimer's disease in Han Chinese	35
Metformin in the Prevention of Alzheimer's Disease and Alzheimer's Disease Related Dementias	32

The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6	31
Informal care for people with dementia in Europe	30
Projected Savings to Canadian Provincial Budgets from Reduced Long-Term Care Home Utilization Due to a Disease-Modifying Alzheimer's Treatment	30
The Shape Trail Test Is Sensitive in Differentiating Older Adults with Mild Cognitive Impairment: A Culture-neutral Five-minute Test	30
Disparities in out-of-pocket costs for disease-modifying therapy under Japan's universal health insurance system	30